Pfizer announced that the FDA has approved MIMRYLO™, the first approved hepcidin mimetic for adults with polycythemia vera, for clinical response defined by the absence of phlebotomy eligibility during Weeks 20–32.
Public source
Publisher name
Public post
Not every meaningful advance in oncology is measured in months of survival. Sometimes, innovation changes the burden of living with cancer. 🩸 The FDA has approved MIMRY…
Company
Pfizer
- Industry
- Pharmaceutical Manufacturing
- Location
- New York, US
- Company size
- 10,001+ employees
About Pfizer
We’re celebrating over 175 years of daring scientific innovation—and we’re not done yet. Let’s outdo yesterday. Protect your health at PfizerForAll.com For additional information on our guidelines, please visit http://www.pfizer.com/community-guidelines
See moreLatest activity
Latest activity from Pfizer
43 signals
Presence & Recognition
Pfizer participated in the ERS 2026 conference in Barcelona, engaging with the global respiratory community through scientific exchange, expert discussions, and collaborations focused on asthma and COPD care.
Presence & Recognition
Pfizer employee Mariam Sultani will speak at the Festival of Biologics Basel 2026 on October 13-15 at Messe Basel.
People
Pfizer is hiring a Systems Immunology translational AI engineer.
Discover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
MPN Research Foundation
MPN Research Foundation reported that the FDA has approved Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera.
Legal & Regulatory
Spherix Global Insights
Spherix Global Insights reported that the FDA approved MIMRYLO™, the first hepcidin mimetic for adults with polycythemia vera, introducing a new way to control hematocrit while reducing the need for phlebotomy and improving fatigue.
Legal & Regulatory
Takeda
Takeda announced the recent FDA approval of a new treatment for erythrocytosis in adults with Polycythemia Vera.
Legal & Regulatory
Takeda Oncology
Takeda Oncology announced the recent FDA approval of a new treatment for erythrocytosis in adults with PV following years of clinical advancement and partnership.
Legal & Regulatory
Karyopharm Therapeutics Inc.